| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | JANX | Common Stock | Conversion of derivative security | +1.35M | 1.35M | Jun 15, 2021 | See footnotes | F1, F2, F3 | |||
| transaction | JANX | Common Stock | Conversion of derivative security | +824K | +61.09% | 2.17M | Jun 15, 2021 | See footnotes | F1, F2, F3 | ||
| transaction | JANX | Common Stock | Purchase | $10M | +588K | +27.08% | $17.00 | 2.76M | Jun 15, 2021 | See footnotes | F2, F3, F4 |
| transaction | JANX | Common Stock | Conversion of derivative security | +165K | 165K | Jun 15, 2021 | See footnotes | F1, F3, F5 | |||
| transaction | JANX | Common Stock | Purchase | $2M | +118K | +71.41% | $17.00 | 282K | Jun 15, 2021 | See footnotes | F3, F4, F5 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | JANX | Series A Convertible Preferred Stock | Conversion of derivative security | -1.05M | -100% | 0 | Jun 15, 2021 | Common Stock | 1.35M | See footnotes | F1, F2, F3 | |||
| transaction | JANX | Series B Convertible Preferred Stock | Conversion of derivative security | -643K | -100% | 0 | Jun 15, 2021 | Common Stock | 824K | See footnotes | F1, F2, F3 | |||
| transaction | JANX | Series B Convertible Preferred Stock | Conversion of derivative security | -129K | -100% | 0 | Jun 15, 2021 | Common Stock | 165K | See footnotes | F1, F3, F5 |
| Id | Content |
|---|---|
| F1 | Each share of Series A Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the "Preferred Stock") converted into 1.281 shares of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. Share numbers give effect to such conversion. The Preferred Stock had no expiration date. |
| F2 | The securities are held of record by OrbiMed Private Investments VIII, LP ("OPI VIII"). OrbiMed Capital GP VIII LLC ("GP VIII") is the general partner of OPI VIII and OrbiMed Advisors LLC ("Advisors") is the managing member of GP VIII. By virtue of such relationships, GP VIII and Advisors may be deemed to have voting and investment power with respect to the shares held by OPI VIII and as a result may be deemed to have beneficial ownership of such shares. Advisors exercises investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and Jonathan T. Silverstein. |
| F3 | This report on Form 4 is jointly filed by Advisors, GP VIII, and OrbiMed Genesis GP LLC ("Genesis GP"). Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. Advisors and GP VIII have designated a representative, Peter Thompson, an employee of Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for purpose of Section 16 of the Exchange Act, or for any other purpose. |
| F4 | The shares were purchased in the Issuer's initial public offering. |
| F5 | The securities are held of record by OrbiMed Genesis Master Fund, L.P. ("Genesis Fund"). Genesis GP is the general partner of Genesis Fund and Advisors is the managing member of Genesis GP. By virtue of such relationships, Genesis GP and Advisors may be deemed to have voting and investment power with respect to the shares held by Genesis Fund and as a result may be deemed to have beneficial ownership of such shares. Advisors exercises investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and Jonathan T. Silverstein. |